EWA
KRYS icon

EP Wealth Advisors’s Krystal Biotech KRYS Stock Holding History

EP Wealth Advisors’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,846
Closed -$455K – 1550
2025
Q4 		$455K Buy
+1,846
New +$389K ﹤0.01% 930
2025
Q2 		$375K Buy
2,726
+105
+4% +$15.4K ﹤0.01% 909
2025
Q1 		$473K Buy
+2,621
New +$441K ﹤0.01% 728

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EP Wealth Advisors's KRYS Position: Q1 2026 in Review

EP Wealth Advisors sold out of Krystal Biotech (KRYS) in Q1 2026, closing a stake of 1,846 shares — an estimated $455K sold.

EP Wealth Advisors first reported a position in KRYS in Q1 2025 and held it in 3 quarters. The position peaked at $473K in Q1 2025. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • EP Wealth Advisors reported no remaining Krystal Biotech position as of Q1 2026 after selling out during the quarter.
  • EP Wealth Advisors sold 1,846 Krystal Biotech shares in Q1 2026, an estimated $455K.
  • EP Wealth Advisors first reported a position in Krystal Biotech in Q1 2025 and held it in 3 quarters.
  • EP Wealth Advisors's Krystal Biotech position peaked at $473K in Q1 2025.
  • 367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on EP Wealth Advisors's 13F filing for Q1 2026, filed 14 May 2026.